Literature DB >> 19766443

Dysphonia severity degree and phonation onset latency in laryngeal adductor dystonia.

Noemi Grigoletto De Biase1, Gustavo P Korn, Paula Lorenzon, Marina Padovani, Miriam Moraes, Glaucya Madazio, Luiz Celso P Vilanova.   

Abstract

Although the latency between the initiation of thyroarytenoid electrical activity and the onset of phonation generally is increased in patients with adductor laryngeal dystonia, there is disagreement about whether there is overlap of latency values in these patients and normal subjects. The goal of this article was to compare the severity of dysphonia with the latency between electrophysiological activation of the thyroarytenoid muscle (TA) and the onset of phonation in patients with adductor laryngeal dystonia and compare the values with normal controls. Twenty-one patients with adductor dystonia and 15 control patients underwent laryngeal electromyographic (EMG) examination of the left TA. We measured the latency from initiation spike of the electric activity of the TA muscle to the onset of phonation. Three speech-pathologists/voice specialists arrived at a consensus to rate the perceptual evaluation of voice quality for the study group. The average latency measured for patients with mild dysphonia was 332 milliseconds, for moderate dysphonia was 426 milliseconds, and for the severe dysphonia was 792 milliseconds. We used the Spearman's correlation test to compare the latency time values and the dysphonia's degree of severity (P<0.05). Latency was significantly and directly related to the degree of severity of dysphonia. Copyright (c) 2010 The Voice Foundation. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19766443     DOI: 10.1016/j.jvoice.2008.10.012

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  1 in total

1.  Dynamics of phonatory posturing at phonation onset.

Authors:  Travis L Shiba; Dinesh K Chhetri
Journal:  Laryngoscope       Date:  2015-12-21       Impact factor: 3.325

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.